FDA Rejects Intercept’s OCA for NASH
The Food and Drug Administration (FDA) last month rejected Intercept Pharmaceuticals' nonalcoholic steatohepatitis (NASH) drug, creating a major delay in [...]
Advertisement
The Food and Drug Administration (FDA) last month rejected Intercept Pharmaceuticals' nonalcoholic steatohepatitis (NASH) drug, creating a major delay in [...]
